- CATIE NewsResearchers found that shingles was more serious and occurred earlier in people with HIV. In the Calgary study, hospitalization for shingles cost on average $33,000 per person. Subsidizing shingles…
- Placeholder
- Placeholder
- CATIE NewsA study of HIV pre-exposure prophylaxis (PrEP) in Australia enrolled close to 10,000 people. Thirty men became HIV positive who were not taking PrEP according to Australian guidelines. Research is…
- This CATIE blog post describes the Tele-PrEP program in British Columbia.
- WebinarThis webinar will explore existing pathways in Ontario to HIV prevention, efforts to create new pathways relevant to Indigenous communities, and the role that clinical and non-clinical service…
- Placeholder
- CATIE staff would like to extend our best wishes to Tim Rogers upon his retirement at the end of November 2022. We are sad to see Tim go, as we have been fortunate to benefit from his guidance for…
- The HIV Legal Network, PASAN, and a criminologist from Toronto Metropolitan University undertook a study exploring the perspectives of former prisoners, community-based harm reduction workers, and…
- CATIE NewsLenacapavir (Sunlenca) is the first capsid inhibitor approved for HIV treatment. Lenacapavir works in a way that is different from other HIV medications. After initial oral dosing, lenacapavir…
- A video reviewing the different forms of PrEP available, including daily and on-demand PrEP, injectable PrEP and vaginal rings.